Sanara MedTech Inc. (NASDAQ:SMTI – Get Free Report) shares dropped 4.1% during mid-day trading on Tuesday . The stock traded as low as $28.43 and last traded at $29.00. Approximately 25,395 shares were traded during mid-day trading, an increase of 40% from the average daily volume of 18,159 shares. The stock had previously closed at $30.24.
Sanara MedTech Price Performance
The company’s 50-day moving average is $31.95 and its 200-day moving average is $31.67. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.80 and a quick ratio of 1.49. The firm has a market capitalization of $250.13 million, a price-to-earnings ratio of -49.15 and a beta of 1.60.
Sanara MedTech (NASDAQ:SMTI – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.41) earnings per share (EPS) for the quarter. Sanara MedTech had a negative return on equity of 15.17% and a negative net margin of 9.07%. The company had revenue of $20.16 million during the quarter. On average, research analysts expect that Sanara MedTech Inc. will post -2.03 earnings per share for the current year.
Institutional Inflows and Outflows
About Sanara MedTech
Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.
Further Reading
- Five stocks we like better than Sanara MedTech
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Why Lennar Stock Could Be the Best Play in the Housing Market
- ETF Screener: Uses and Step-by-Step Guide
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Trading Halts Explained
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.